Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Arrowhead Pharmaceuticals, Inc. (ARWR) Healthcare & Pipeline Overview

Arrowhead Pharmaceuticals, Inc. is a pioneering biotechnology company focused on RNA interference therapeutics, with a robust pipeline aimed at treating intractable diseases, including liver diseases and genetic disorders, showcasing its commitment to innovative healthcare solutions.

What Is the Investment Thesis for ARWR?

The company has a market capitalization of $11.7B and operates with a gross margin of 100%, indicative of its strong pricing power and operational efficiency. Key growth catalysts include the advancement of its clinical trials, particularly ARO-AAT and ARO-APOC3, which have the potential to address significant market needs in liver diseases and hypertriglyceridemia, respectively. The global RNAi therapeutics market is projected to grow substantially, which could enhance Arrowhead's market position. However, the company faces risks related to regulatory approvals and competition from established players in the biotechnology sector. Overall, Arrowhead's unique focus on RNAi and its robust pipeline create significant value drivers that could lead to substantial growth in the coming years.

Based on FMP financials and quantitative analysis

ARWR Key Highlights

Market capitalization of $11.7B, reflecting strong investor interest and confidence.

• Gross margin of 100%, indicating no cost of goods sold for its therapeutics, enhancing profitability potential.
• Profit margin currently at -48.4%, reflecting ongoing investment in R&D and clinical trials.
• Beta of 1.30, suggesting higher volatility compared to the overall market, which may appeal to risk-tolerant investors.
• No dividend yield, consistent with growth-focused biotechnology firms reinvesting profits into R&D.

Who Are ARWR's Competitors?

ARWR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ARWR's Key Strengths?

Innovative RNAi technology with a strong pipeline of therapeutics.

• Strategic partnerships with leading pharmaceutical companies.
• Experienced management team with a track record of success.
• Robust intellectual property portfolio protecting proprietary technologies.

What Are ARWR's Weaknesses?

Negative profit margin indicating ongoing investment in R&D.

• Dependence on clinical trial outcomes for product success.
• Limited product revenue as most candidates are in development stages.
• Potential challenges in regulatory approval processes.

What Are the Key Risks for ARWR?

Negative return on equity (-55.4%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

What Are the Growth Opportunities for ARWR?

• Growth opportunity 1: The global RNA interference therapeutics market is projected to reach $7.5 billion by 2027, driven by rising demand for targeted therapies. Arrowhead's focus on RNAi technology positions it to capitalize on this growth, particularly with its lead candidates in advanced clinical trials, potentially capturing significant market share as they receive regulatory approvals.
• Growth opportunity 2: Arrowhead's collaboration with Janssen Pharmaceuticals for the development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 therapeutics enhances its research capabilities and accelerates product development. This partnership could lead to innovative solutions for liver diseases, tapping into a market that is increasingly recognizing the need for effective treatments.
• Growth opportunity 3: The company's pipeline includes ARO-ENaC and ARO-Lung2, targeting chronic obstructive pulmonary disease (COPD), a condition affecting millions globally.
• Growth opportunity 4: Arrowhead's ARO-DUX4 for facioscapulohumeral muscular dystrophy represents a strategic entry into the rare disease market, which is gaining attention from investors and healthcare providers.
• Growth opportunity 5: The ongoing development of ARO-COV for COVID-19 treatment and other pulmonary-borne pathogens aligns Arrowhead with current global health priorities. As the pandemic continues to evolve, the demand for innovative therapeutics in infectious diseases could open new revenue channels for the company.

What Threats Does ARWR Face?

• Intense competition from established biotechnology firms.
• Regulatory hurdles that could delay product approvals.
• Market volatility impacting investor sentiment and funding.
• Rapid technological advancements requiring continuous innovation.

What Are ARWR's Competitive Advantages?

• Strong intellectual property portfolio protecting RNAi technology innovations.
• Established collaborations with leading pharmaceutical companies enhancing research capabilities.
• Robust pipeline of therapeutics addressing significant unmet medical needs.
• Expertise in RNAi technology providing a competitive edge in drug development.
• Focus on rare and complex diseases differentiating Arrowhead from competitors.

What Does ARWR Do?

Founded in 1989, Arrowhead Pharmaceuticals, Inc. has established itself as a leader in the biotechnology sector, focusing on the development of innovative medicines for intractable diseases. Headquartered in Pasadena, California, the company has evolved significantly over the years, leveraging advancements in RNA interference (RNAi) technology to create therapeutics that address unmet medical needs. Arrowhead's pipeline includes several promising candidates, such as ARO-AAT, which is in Phase II clinical trials for treating liver diseases linked to alpha-1 antitrypsin deficiency, and ARO-APOC3, currently in Phase 2b and Phase 3 trials for hypertriglyceridemia. The company's diverse portfolio also features ARO-ANG3, ARO-HSD, ARO-ENaC, and ARO-C3, targeting various conditions including chronic obstructive pulmonary disease and genetic muscular dystrophies. Arrowhead has formed strategic collaborations with major pharmaceutical companies, including Janssen Pharmaceuticals and Takeda Pharmaceuticals, to enhance its research capabilities and expedite the development of its RNAi therapeutics. With a workforce of 609 employees, Arrowhead Pharmaceuticals is well-positioned to continue its trajectory of growth and innovation in the biotechnology landscape, focusing on delivering effective treatments for patients suffering from complex diseases.

What Products and Services Does ARWR Offer?

• Develop RNA interference therapeutics for the treatment of intractable diseases.
• Focus on liver diseases, hypertriglyceridemia, and genetic disorders.
• Conduct clinical trials to validate the safety and efficacy of its therapeutics.
• Collaborate with major pharmaceutical companies for research and development.
• Leverage advanced RNAi technology to create innovative treatment solutions.
• Aim to address unmet medical needs in various therapeutic areas.

How Does ARWR Make Money?

• Generate revenue through the development and commercialization of RNAi therapeutics.
• Engage in strategic partnerships and collaborations for research and development.
• Focus on advancing clinical trials to bring new therapeutics to market.
• Utilize licensing agreements to expand product offerings and market reach.
• Invest in R&D to drive innovation and maintain competitive advantage.

What Industry Does ARWR Operate In?

The biotechnology industry is experiencing robust growth, driven by advancements in genetic therapies and personalized medicine. The global RNA interference therapeutics market is expected to expand significantly, fueled by increasing investments in research and development, as well as a growing focus on targeted therapies for complex diseases. Arrowhead Pharmaceuticals operates in a competitive landscape alongside peers such as Axsome Therapeutics, Krystal Biotech, and TG Therapeutics, each vying for market share in the rapidly evolving biotechnology sector. The increasing prevalence of chronic diseases and the demand for innovative treatment options position Arrowhead favorably within this dynamic industry.

Who Are ARWR's Key Customers?

• Healthcare providers seeking innovative treatment options for patients.
• Pharmaceutical companies interested in collaboration and licensing opportunities.
• Patients suffering from intractable diseases and genetic disorders.
• Investors looking for growth opportunities in the biotechnology sector.
• Regulatory bodies involved in the approval of new therapeutics.

Over the past six months, Arrowhead Pharmaceuticals, Inc. insiders filed 8 SEC Form 4 transactions — 7 sales and 1 purchases. On net that is roughly 28K shares disposed (about $3.1M), a signal worth weighing alongside the fundamentals.

Arrowhead Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 533.8% above estimates on average.

Arrowhead Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.82 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Arrowhead Pharmaceuticals, Inc. stands at -55.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.0%, the inverse of the P/E and a quick read on earnings relative to price.

Arrowhead Pharmaceuticals, Inc. (ARWR) Valuation Context

Valued at $11.7B, ARWR is classified as a large-cap stock. Analyst price targets span from $46.00 to $126.00, with a consensus of $104.43. At the current price of $82.76, that implies approximately 26% upside potential. Relative to its peer group, ARWR's quantitative score of 31/100 is below the peer average of 73/100.

ARWR Revenue & Earnings Trend

In Q3 FY2026, ARWR generated $75.3M in top-line revenue, marking a sequential increase of 2.1%. The company recorded a net loss of $194.3M, with diluted EPS of $-1.36. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ARWR averaged $-0.56 in diluted EPS.

Company Profile

Arrowhead Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pasadena, US. The company is led by CEO Christopher R. Anzalone. ARWR has traded publicly since 1993.

ARWR Financials

ARWR Latest News

ARWR Analyst Consensus

ARWR MoonshotScore

Latest Arrowhead Pharmaceuticals, Inc. Analysis

Common Questions About ARWR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources